News
MSD adds new indication for Welireg in rare tumours
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
Sunday 8 November 2026
